

Review of: "The potential of GLP-1 RAs in treating Tobacco use dependence and Obesity"

Fernando Gomes de Souza Jr¹

¹ Universidade Federal do Rio de Janeiro

Potential competing interests: No potential competing interests to declare.

The main contributions of this preprint are the in-depth study of the potential utility of glucagon-like peptide-1 receptor (GLP-1 RA) agonists in alleviating tobacco dependence and obesity. GLP-1-RAs are recognized as existing therapeutic agents for diabetes mellitus and obesity, and should also have additional utility in promoting smoking cessation. Highlighting the widespread prevalence of smoking and obesity in Singapore, the article suggests that GLP-1 ARs are potentially valuable tools for reducing the health impact of these prevalent risk factors.

However, there are limits. More importantly, research supporting the use of GLP-1 ARs in the treatment of tobacco addiction and obesity is still in the preclinical phase. Further in-depth studies are essential to support the findings presented in this article. Another limiting factor is the particular focus on Singapore, which raises questions about the transferability of these findings to other populations or regions.

So I have some friendly suggestions that might help you improve your work even more:

First, have you considered expanding your business scope beyond Singapore? By including other countries or populations, you might gain new information and your information would be applicable to a wider population. A little variety could really increase the relevance of your work!

Additionally, delving into the mechanisms of how GLP-1 ARs affect dopamine-dependent neurological reward pathways could be a great addition. It's a complex topic, but if you dive into it, your research might become even stronger and you might inspire future directions of research. To provide a balanced picture, it might be enlightening to mention some of the potential challenges or disadvantages of GLP-1 RAs. The inclusion of this would provide a comprehensive overview for clinicians and researchers wishing to further investigate GLP-1 RAs.

Comparisons are always interesting to read. A side-by-side comparison with existing treatments for tobacco dependence and obesity could clarify the unique benefits of GLP-1 RAs and further strengthen your case for their potential use.

Discussing the implications can add an extra layer of richness to your article as you go into detail. For example, exploring the potential effect of GLP-1 ARs on national health care spending or discussing potential public reception would be fascinating topics to explore. If enough data is available, a systematic review or meta-analysis can be a game changer! This can solidify your evidence base and make your paper even more persuasive.

Finally, a good way to conclude would be to suggest the direction of future research. You've presented a compelling case

for more solid study, so why not share your thoughts on what they might look like? The ideal sample size, study design, and outcome measures may pave the way for future work in this area.

Remember, these are just suggestions. Keep up the good work and I look forward to seeing how your research progresses!